Pricing Log in Create free account

Monopar Therapeutics Inc. (MNPR) vs Prothena Corporation plc (PRTA)

Monopar Therapeutics Inc. and Prothena Corporation plc are both Biotechnology companies. Monopar Therapeutics Inc. is the larger, with a market value of $469.1M against $421.5M — 1.1× the size. Monopar Therapeutics Inc. has the higher net margin (0.00% vs −80.7%) and the higher return on invested capital (0.00% vs 0.00%). Across the 11 metrics below, Monopar Therapeutics Inc. leads on 7 and Prothena Corporation plc on 4.

Valuation

Metric MNPR PRTA Biotechnology median
P/E n/m n/m 10.64
P/S n/m 7.89 9.59
P/B 4.55 1.50 2.15
Price to free cash flow n/m n/m 26.07
EV/EBITDA n/m n/m 0.65
EV/Sales n/m 2.60 9.45
Earnings yield (3.11%) (10.06%) (34.69%)
Free cash flow yield (2.05%) (14.13%) (24.02%)

Profitability

Metric MNPR PRTA Biotechnology median
Gross margin — 100.00% 65.59%
Operating margin 0.00% (101.80%) 0.00%
Net margin 0.00% (80.67%) 0.00%
Free cash flow margin 0.00% (111.49%) 0.00%
Return on equity (19.50%) (14.39%) (51.96%)
Return on assets (18.90%) (12.54%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric MNPR PRTA Biotechnology median
Revenue growth (TTM) — 427.32% 4.59%
EPS growth (last fiscal year) 54.99% (99.56%) 29.88%
Revenue growth, 5-year CAGR — 62.56% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric MNPR PRTA Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 33.56 25.05 4.86
Net debt to EBITDA 8.06 1.46 1.01

Dividend

Metric MNPR PRTA Biotechnology median
Dividend yield — — 0.38%
Payout ratio — — —

Size

Metric MNPR PRTA Biotechnology median
Market cap 469.11m 421.47m 174.29m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack